- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04899180
Prevalence of Transthyretin Cardiac Amyloidosis in Clinically Significant Aortic Stenosis
July 31, 2023 updated by: Omar Abou Ezzeddine, Mayo Clinic
Prevalence of Transthyretin Cardiac Amyloidosis in Clinically Significant Aortic Stenosis: A Community Study
The purpose of this study is to determine the prevalence of transthyretin cardiac amyloidosis (TTR-CA) among patients with moderate and severe aortic stenosis in Southeast Minnesota using 99mTc-PYP single-photon positive emission computed tomography with computed tomography (SPECT/CT).
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Residents of Southeast Minnesota over 75 years of age with an inpatient or outpatient diagnosis of moderate or severe aortic stenosis will be consecutively identified using an automated bi-weekly review of the echo lab calendar (on Mondays and Fridays) at Mayo Clinic Rochester (MCR) and Mayo Clinic Health System (MCHS) sites.
Participants will be consented to undergo venipuncture, urine collection and 99mTc-PYP SPECT/CT imaging to rule in/out the diagnosis of TTR-CA.
Hence, the prevalence of TTR-CA will be defined.
To place this prevalence in perspective of the global aortic stenosis cohort in the community, a rigorous screening log will be maintained to allow generation of a comprehensive CONSORT diagram.
Importantly, baseline characteristics of patients who qualify for our study but decline to consent will still be collected provided that consent for use of their records for medical research had previously been granted.
Study Type
Interventional
Enrollment (Estimated)
200
Phase
- Early Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Elizabeth Erickson
- Phone Number: (507) 266-7605
- Email: erickson.elizabeth2@mayo.edu
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Recruiting
- Mayo Clinic in Rochester
-
Contact:
- Elizabeth Erickson
- Phone Number: 507-266-7605
- Email: erickson.elizabeth2@mayo.edu
-
Contact:
- Carl Griffin, II
- Phone Number: (507) 255-5690
- Email: GriffinII.Carl@mayo.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
75 years and older (Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Resident of Southeastern Minnesota (Olmsted, Dodge, Fillmore, Mower, Freeborn, Wabasha, or Steele County)
- Age ≥ 75 years
Current diagnosis of moderate or severe aortic stenosis by most recent (within 6 months at most) echocardiogram as defined by:
- Moderate AS: 1.0 cm2 < aortic valve area (AVA) ≤ 1.5 cm2
- Severe AS: AVA ≤ 1.0 cm2
Exclusion Criteria:
- Any cardiac surgery or major chest trauma within 4 weeks of PYP scan
- Myocardial infarction within 4 weeks of PYP scan defined by typical angina, EKG changes and significant change in serial troponins. (Note that chronic troponin elevation is extremely common in cardiac amyloidosis).
- Prior or current exposure to Plaquenil (Hydroxychloroquine)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: SPECT/CT
99mTc-PYP single-photon positive emission computed tomography with computed tomography
|
Radioisotope used by SPECT/CT imaging
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Prevalence of TTR-CA in patients with moderate and severe aortic stenosis
Time Frame: Baseline
|
Determine the prevalence of Transthyretin Cardiac Amyloidosis in a community based cohort of consecutive patients with moderate or severe aortic stenosis using 99mTc-Pyrophosphate (99mTc-PYP) single-photon positive emission computed tomography with computed tomography (SPECT/CT)
|
Baseline
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Omar F Abou Ezzeddine, MD, Mayo Clinic
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 14, 2023
Primary Completion (Estimated)
August 1, 2024
Study Completion (Estimated)
August 1, 2024
Study Registration Dates
First Submitted
May 19, 2021
First Submitted That Met QC Criteria
May 19, 2021
First Posted (Actual)
May 24, 2021
Study Record Updates
Last Update Posted (Actual)
August 2, 2023
Last Update Submitted That Met QC Criteria
July 31, 2023
Last Verified
July 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20-004778
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Aortic Stenosis
-
Hospices Civils de LyonRecruiting
-
Abbott Medical DevicesActive, not recruitingSevere Aortic Stenosis | Symptomatic Degenerative Aortic StenosisSpain, Italy, United Kingdom, Germany, Switzerland, Czechia, Australia, Belgium, Poland
-
Edwards LifesciencesActive, not recruitingAortic Stenosis | Aortic Regurgitation | Symptomatic Aortic StenosisChina
-
Anteris Technologies Ltd.Active, not recruitingAortic Valve Calcification | Severe Aortic Valve Stenosis | Symptomatic Aortic StenosisGeorgia
-
Anteris Technologies Ltd.Active, not recruitingAortic Stenosis | Aortic Valve Calcification | Severe Aortic Valve Stenosis | Symptomatic Aortic StenosisUnited States
-
Edwards LifesciencesCompletedAortic Stenosis | Aortic Regurgitation | Symptomatic Aortic StenosisChina
-
Ningbo Jenscare Biotechnology Co., Ltd.UnknownAortic Regurgitation | Severe Aortic Stenosis
-
Genesis Medtech CorporationRecruitingDiseases of Aortic Valve | Aortic Stenosis DiseaseChina
-
Pan XiangbinRecruiting
-
Colibri Heart Valve LLCRecruiting
Clinical Trials on 99mTc-PYP
-
Mayo ClinicPfizerCompletedHeart Failure With Preserved Ejection FractionUnited States
-
Mathew S. MaurerNational Heart, Lung, and Blood Institute (NHLBI); Yale University; Boston Medical... and other collaboratorsRecruitingAmyloid Cardiomyopathy, Transthyretin-RelatedUnited States
-
University of Tennessee Graduate School of MedicineAttralus, Inc.RecruitingSystemic AmyloidosisUnited States
-
Massachusetts General HospitalPfizer; Akcea Therapeutics; Alnylam Pharmaceuticals; Eidos Therapeutics, a BridgeBio...RecruitingHeart Failure | Amyloidosis | Heart Failure, Diastolic | Transthyretin AmyloidosisUnited States
-
University of Texas Southwestern Medical CenterMid America Heart InstituteWithdrawnAortic Valve Stenosis | Cardiac Amyloidosis
-
Oregon Health and Science UniversityIonis Pharmaceuticals, Inc.RecruitingAmyloidosis | Transthyretin Amyloid CardiomyopathyUnited States
-
Far Eastern Memorial HospitalNot yet recruiting
-
Tel-Aviv Sourasky Medical CenterUnknown
-
Columbia UniversityNational Institute on Aging (NIA)RecruitingLumbar Spinal Stenosis | Cardiomyopathy, Hypertrophic | Cardiac Amyloidosis | ATTR Amyloidosis Wild Type | ATTR Gene Mutation | ATTRV122I AmyloidosisUnited States
-
Peking Union Medical College HospitalCompletedBreast CancerChina